Dyslipidemia in women after 50: Age, menopause or both?;Dyslipidémies de la femme après 50 ans : le rôle de l'âge et de la ménopause

Annales de Cardiologie et d'Angeiologie

Volumn 58, Issue 3, 2009, Pages 159-164

  Agrinier, N ^a,b   Cournot, M ^c,d   Ferrieres J ^d  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c centre hospitalier du Val d'Ariège   (France)

^d INSERM   (France)

Author keywords

Age; Cardiovascular risk; Cholesterol; Dyslipidemia; Menopause; Review; Triglycerides

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LONGITUDINAL STUDY; MENOPAUSE; PREVALENCE; RISK FACTOR; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 67349239343     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2008.09.006     Document Type: Short Survey

References (57)

1. Ford E.S., and Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol. 50 22 (2007) 2128-2132
2. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., and Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. 353 9164 (1999) 1547-1557
3. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 351 9113 (1998) 1425-1427
4. Grundy S.M., Bazzarre T., Cleeman J., D'Agostino Sr. R.B., Hill M., Houston-Miller N., et al., Writing Group I. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment. Circulation. 101 1 (2000) E3-E11
5. Lloyd-Jones D.M., Wilson P.W., Larson M.G., Leip E., Beiser A., D'Agostino R.B., et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med. 163 16 (2003) 1966-1972
6. Pencina M.J., D'Agostino R.B., Beiser A.S., Cobain M.R., and Vasan R.S. Estimating lifetime risk of developing high serum total cholesterol: adjustment for baseline prevalence and single-occasion measurements. Am J Epidemiol. 165 4 (2007) 464-472
7. Greendale G.A., Lee N.P., and Arriola E.R. The menopause. Lancet. 353 9152 (1999) 571-580
8. Rosano G.M., Chierchia S.L., Leonardo F., Beale C.M., and Collins P. Cardioprotective effects of ovarian hormones. Eur Heart J. 17 Suppl. D (1996) 15-19
9. Research on Menopause. Report of a WHO Scientific Group. Geneva. Switzerland: World Health Organization; 1981. Report No.: 670.
10. Kaufert P., Lock M., McKinlay S., Beyenne Y., Coope J., Davis D., et al. Menopause research: the Korpilampi workshop. Soc Sci Med. 22 11 (1986) 1285-1289
11. Utian W.H. The International Menopause Society menopause-related terminology definitions. Climacteric. 2 4 (1999) 284-286
12. Trémollières F.A., Pouilles J.M., Cauneille C., and Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 142 2 (1999) 415-423
13. Schaefer E.J., Lamon-Fava S., Cohn S.D., Schaefer M.M., Ordovas J.M., Castelli W.P., et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 35 5 (1994) 779-792
14. Dallongeville J., Marecaux N., Isorez D., Zylbergberg G., Fruchart J.C., and Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis. 118 1 (1995) 123-133
15. Ozbey N., Sencer E., Molvalilar S., and Orhan Y. Body fat distribution and cardiovascular disease risk factors in pre- and postmenopausal obese women with similar BMI. Endocr J. 49 4 (2002) 503-509
16. Gierach G.L., Johnson B.D., Bairey Merz C.N., Kelsey S.F., Bittner V., Olson M.B., et al. Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol. 47 3 Suppl (2006) S50-S58
17. Pasquali R., Casimirri F., Pascal G., Tortelli O., Morselli Labate A., Bertazzo D., et al., Virgilio Menopause Health Group. Influence of menopause on blood cholesterol levels in women: the role of body composition, fat distribution and hormonal milieu. J Intern Med. 241 3 (1997) 195-203
18. Peters H.W., Westendorp I.C., Hak A.E., Grobbee D.E., Stehouwer C.D., Hofman A., et al. Menopausal status and risk factors for cardiovascular disease. J Intern Med. 246 6 (1999) 521-528
19. Weiss N. Relationship of menopause to serum cholesterol and arterial blood pressure: the United States' Health Survey of adults. Am J Epidemiol 96 4 (1972) 237-241
20. Kraemer H.C., Yesavage J.A., Taylor J.L., and Kupfer D. How can we learn about developmental processes from cross-sectional studies, or can we?. Am J Psychiatry. 157 2 (2000) 163-171
21. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 14 (2004) 1701-1712
22. Hjortland M.C., McNamara P.M., and Kannel W.B. Some atherogenic concomitants of menopause: The Framingham Study. Am J Epidemiol. 103 3 (1976) 304-311
23. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., and Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med. 321 10 (1989) 641-646
24. Lindquist O. Intraindividual changes of blood pressure, serum lipids, and body weight in relation to menstrual status: results from a prospective population study of women in Goteborg, Sweden. Prev Med. 11 2 (1982) 162-172
25. Akahoshi M., Soda M., Nakashima E., Shimaoka K., Seto S., and Yano K. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation. 94 1 (1996) 61-66
26. Fukami K., Koike K., Hirota K., Yoshikawa H., and Miyake A. Perimenopausal changes in serum lipids and lipoproteins: a 7-year longitudinal study. Maturitas. 22 3 (1995) 193-197
27. Torng P.L., Su T.C., Sung F.C., Chien K.L., Huang S.C., Chow S.N., et al. Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight - the Chin-Shan Community Cardiovascular Cohort study. Atherosclerosis. 161 2 (2002) 409-415
28. Stevenson J.C., Crook D., and Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 98 1 (1993) 83-90
29. Jensen J., Nilas L., and Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 12 4 (1990) 321-331
30. Campos H., McNamara J.R., Wilson P.W., Ordovas J.M., and Schaefer E.J. Differences in low-density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 67 1 (1988) 30-35
31. van Beresteijn E.C., Korevaar J.C., Huijbregts P.C., Schouten E.G., Burema J., and Kok F.J. Perimenopausal increase in serum cholesterol: a 10-year longitudinal study. Am J Epidemiol. 137 4 (1993) 383-392
32. Bruckert E., and Turpin G. Estrogens and progestins in postmenopausal women: influence on lipid parameters and cardiovascular risk. Horm Res. 43 1-3 (1995) 100-103
33. Haines C.J., Chung T.K., Masarei J.R., Tomlinson B., and Lau J.T. The effect of percutaneous oestrogen replacement therapy on Lp(a) and other lipoproteins. Maturitas. 22 3 (1995) 219-225
34. Haines C.J., Chung T.K., Masarei J.R., Tomlinson B., and Lau J.T. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis. 119 2 (1996) 215-222
35. Kim C.J., Min Y.K., Ryu W.S., Kwak J.W., and Ryoo U.H. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med. 156 15 (1996) 1693-1700
36. Orth-Gomer K., Mittleman M.A., Schenck-Gustafsson K., Wamala S.P., Eriksson M., Belkic K., et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 95 2 (1997) 329-334
37. Sacks F.M., McPherson R., and Walsh B.W. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 154 10 (1994) 1106-1110
38. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., and Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325 17 (1991) 1196-1204
39. Kovanen P.T., Brown M.S., and Goldstein J.L. Increased binding of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol. J Biol Chem. 254 22 (1979) 11367-11373
40. Tikkanen M.J., Nikkila E.A., Kuusi T., and Sipinen S.U. High-density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab. 54 6 (1982) 1113-1117
41. Berenson G.S., Wattigney W.A., Tracy R.E., Newman III W.P., Srinivasan S.R., Webber L.S., et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol. 70 9 (1992) 851-858
42. Neufeld H.N., Wagenvoort C.A., and Edwards J.E. Coronary arteries in fetuses, infants, juveniles, and young adults. Lab Invest. 11 (1962) 837-844
43. Szczeklik A., Gryglewski R.J., Domagala B., Dworski R., and Basista M. Dietary supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability. Thromb Haemost. 54 2 (1985) 425-430
44. Vlodaver Z., Kahn H.A., and Neufeld H.N. The coronary arteries in early life in three different ethnic groups. Circulation. 39 4 (1969) 541-550
45. Everson G.T., McKinley C., and Kern Jr. F. Mechanisms of gallstone formation in women. J Clin Invest. 87 1 (1991) 237-246
46. Wagner J.D., Clarkson T.B., St Clair R.W., Schwenke D.C., Shively C.A., and Adams M.R. Estrogen and progesterone replacement therapy reduces low-density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest. 88 6 (1991) 1995-2002
47. Gorodeski G.I. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol. 16 3 (2002) 329-355
48. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20 1 (1991) 47-63
49. Wilson P.W., Garrison R.J., and Castelli W.P. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med. 313 17 (1985) 1038-1043
50. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 1 (2002) 49-57
51. Hsia J., Langer R.D., Manson J.E., Kuller L., Johnson K.C., Hendrix S.L., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 166 3 (2006) 357-365
52. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349 6 (2003) 523-534
53. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273(3):199-208.
54. AFSSAPS. Traitement hormonal substitutif de la ménopause. Caractéristiques de l'utilisation en France. Effets sur la survenue de cancers du sein et d'évènements cardiovasculaires en France Propositions d'études complémentaires. Paris: Agence française de Sécurité Sanitaire des Produits de Santé; 2005.
55. Odmark I.S., Backstrom T., Haeger M., Jonsson B., and Bixo M. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. Maturitas. 48 2 (2004) 137-146
56. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science. 308 5728 (2005) 1583-1587
57. Anderson K.M., Wilson P.W., Garrison R.J., and Castelli W.P. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample. The Framingham Offspring Study. Atherosclerosis. 68 1-2 (1987) 59-66